Synergistic antitumor effect of Hsp90 targeting-inhibitory peptide P7 combined with docetaxel in lung adenocarcinoma cell line A549

Abstract

Abstract: Objective To investigate the effects of combination of Hsp90 bifunctional targeting-inhibitory peptide LPLTPLP (P7) with chemotherapy drug docetaxel(DTX) on lung adenocarcinoma cell line A549. Methods DTX and peptide P7 alone or combined were incubated with A549 cell for 48 hours, thereafter the effect of the drug on cell viability was evaluated using the CCK-8 method. Flow cytometry was carried out to quantify apoptotic cells. The expression of apoptotic and drug resistant protein were assessed by Western blot analysis. Results DTX and P7 exhibited a synergistic effect on cell survival. The apoptosis rate of the combined drug group was 25.8%, which was significantly higher than that of DTX group(P＜0.05). Apoptosis-related proteins Bcl-2 and PARP were significantly down-regulated(P＜0.05), and cleaved-PARP protein was significantly up-regulated(P＜0.05). Meanwhile, drug-resistant protein major vault protein(MVP) was significantly down-regulated(P＜0.05). Conclusions DTX ombined with targeted peptide P7 can significantly increase the apoptosis rate of A549 cells, which may be related to expression level of Bcl-2, inactivation of DNA repair enzyme PARP and down-regulation of multidrug-resistant protein MVP.

Key words: lung adenocarcinoma, synergy, apoptosis, drug-resistance, heptapeptide

CLC Number:

R963

WU You-ming, LIU Na-si, CAO Ming-yue, HUANG Wei, LIU Yan-yong, YANG Nan. Synergistic antitumor effect of Hsp90 targeting-inhibitory peptide P7 combined with docetaxel in lung adenocarcinoma cell line A549[J]. Basic & Clinical Medicine, 2020, 40(5): 639-643.

References

[1]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68:394-424.
[2]Hayashi Y, Kuriyama H, Umezu H, et al. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer[J]. Intern Med, 2009,48:203-208.
[3]Jemal A, Siegel R, Ward E, et al.Cancer statistics, 2008[J]. CA Cancer J Clin, 2008,58:71-96.
[4]Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together[J]. Cancer, 2000,88:2619-2628.
[5]Whitesell L, and Lindquist SL. HSP90 and the chaperoning of cancer[J]. Nat Rev Cancer, 2005,5:761-772.
[6]Banerji U, Sain N, Sharp SY, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models[J]. Cancer Chemother Pharmacol, 2008,62:769-778.
[7]Iyer G, Morris MJ, Rathkopf D, et al. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors[J]. Cancer Chemother Pharmacol, 2012,69:1089-1097.
[8]Jiang Y, Yang N, Zhang H, et al.Enhanced in vivo antitumor efficacy of dual-functional peptide-modified doce-taxel nanoparticles through tumor targeting and Hsp90 inhibition[J]. J Control Release, 2016,221:26-36.
[9]Huang W, Yuan X, Sun T, et al. Proteasome inhibitor YSY01A abrogates constitutive STAT3 signaling via down-regulation of Gp130 and JAK2 in human A549 lung cancer cells[J]. Front Pharmacol, 2017,8:1-10.
[10]Tang L, Liu J, Zhu L, et al.Curcumin inhibits growth of human NCI-H292 lung squamous cell carcinoma cells by increasing FOXA2 expression[J]. Front Pharmacol, 2018,9:1-9.
[11]Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors[J]. Adv Enzyme Regul, 1984,22:27-55.
[12]Mahalingam D, Swords R, Carew JS, et al. Targeting HSP90 for cancer therapy[J]. Br J Cancer, 2009,100:1523-1529.
[13]Solit DB, Chiosis G. Development and application of Hsp90 inhibitors[J]. Drug Discov Today, 2008,13:38-43.
[14]Pacey S, Wilson RH, Walton M, et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors[J]. Clin Cancer Res, 2011,17:1561-1570.
[15]Scheffer GL, Wijngaard PL, Flens MJ, et al. The drug resistance-related protein LRP is the human major vault protein[J]. Nat Med, 1995,1:578-582.